News By: Gary Cramer

Life sciences organizations have made progress in connecting data and processes across the product lifecycle, in part for preparation to launch artificial intelligence (AI) use cases. The focus on streamlining operations is quickly shifting to create even greater data flow through connected execution across stakeholders.

Clinical development organizations are no longer asking whether artificial intelligence, automation, and modern data architectures belong in research and development. The question in 2026 is far more urgent: "Which organizations can operationalize them fast enough to materially improve speed, quality, cost, and decision-making before competitive pressure forces transformation upon them?"

As external factors such as global disruptions and demand volatility amplify the bottlenecks that slow clinical trials, artificial intelligence (AI) is emerging as a tool to improve their flow and coordination. AI-enabled planning and prediction methods can reduce friction across the trial lifecycle by identifying trends and patterns earlier, so proactive measures can be taken to mitigate the impact.

Clinical research increasingly relies on digital self-service tools to streamline participant intake. Yet the apparent simplicity of electronic check-in often depends on complex back-end architecture for integration, security, compliance, and user flow. When intake systems are poorly designed or integrated insufficiently, they can increase site workload, introduce manual tasks, and weaken data reliability.

There is a version of clinical research that lives apart from care—down a different hallway, run by a different team, governed by a different calendar. And then there is the version that many of us are actively building: research as a living part of how patients move through a health system, from first diagnosis through long-term follow-up.